Literature DB >> 8263152

Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome.

P Ovesen1, J Moller, H J Ingerslev, J O Jørgensen, A Mengel, O Schmitz, K G Alberti, N Moller.   

Abstract

Many reports have suggested that hyperandrogenaemic patients with the polycystic ovary syndrome (PCOS) may be insulin resistant. However, there have also been suggestions that their insulin resistance may relate to obesity and android fat distribution. To assess whether PCOS induces metabolic disturbances independently of obesity, we studied seven lean patients with PCOS (age, 27.1 +/- 2.0 yr; body mass index, 22.2 +/- 0.78 kg/m2; waist/hip ratio, 0.79 +/- 0.02; fat-free mass, 46.38 +/- 1.13 kg) and seven normal women (age, 25.7 +/- 1.4 yr; body mass index, 21.3 +/- 0.69 kg/m2; waist/hip ratio, 0.74 +/- 0.02; fat-free mass, 50.1 +/- 1.51 kg) for 3 h in the basal period and 2 h during a hyperinsulinemic (0.4 mU/kg.min) euglycemic clamp. In the basal state, comparable metabolic indices were recorded: serum insulin, 35.9 +/- 7.7 (PCOS) vs. 37.3 +/- 2.87 pmol/L (controls); plasma C-peptide, 364.1 +/- 66.2 vs. 397.2 +/- 66.2 pmol/L; plasma glucose, 4.95 +/- 0.09 vs. 4.77 +/- 0.09 mmol/L; forearm arterio-venous difference in glucose, 0.17 +/- 0.04 vs. 0.15 +/- 0.07 mmol/L; isotopically determined endogenous glucose production, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 mg/kg.min; and serum nonesterified fatty acids, 545 +/- 40 vs. 617 +/- 54 mumol/L (all P > 0.05). During the clamp, all recordings were again similar: serum insulin, 282.7 +/- 21.5 vs. 270.5 +/- 13.6 pmol/L; plasma C-peptide, 331.0 +/- 33.1 vs. 364.1 +/- 66.2 pmol/L; plasma glucose, 4.99 +/- 0.07 vs. 4.99 +/- 0.05 mmol/L; glucose arterio-venous difference, 1.01 +/- 0.18 vs. 0.85 +/- 0.12 mmol/L; endogenous glucose production, -0.9 +/- 0.1 vs. -0.5 +/- 0.2 mg/kg.min; amount of exogenous glucose necessary to maintain euglycemia, 4.0 +/- 0.4 vs. 3.8 +/- 0.5 mg/kg.min; and nonesterified fatty acids, 205 +/- 7 vs. 246 +/- 18 mumol/L (all P > 0.05). By showing normal basal and insulin-stimulated substrate metabolism in lean hyperandrogenemic PCOS patients, these data suggest that insulin resistance may be an epiphenomenon, rather than a primary feature of PCOS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263152     DOI: 10.1210/jcem.77.6.8263152

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome.

Authors:  Samantha C Fisch; Ariella Farzan Nikou; Elizabeth A Wright; Julia D Phan; Karen L Leung; Tristan R Grogan; David H Abbott; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2018-12       Impact factor: 7.329

Review 2.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

Review 3.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 4.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

5.  Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats.

Authors:  Jay S Mishra; Amar S More; Sathish Kumar
Journal:  Biol Reprod       Date:  2018-04-01       Impact factor: 4.285

6.  Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.

Authors:  Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

7.  GH-IGF-I axis in non-obese women with functional hyperandrogenism.

Authors:  M Legan; A Kocijancic; J Prezelj; J Osredkar; S Fisker
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 9.  Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?

Authors:  J Holte
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 10.  The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.

Authors:  R B Barnes
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.